Venom from the deathstalker carries radiopharmaceuticals to the brain

In order to target cancerous brain tumours with radionuclides, the problematic blood-brain barrier must first be crossed. Life Science Sweden has visited a KI r...

Charged with illegal pharmaceutical sales – alleged earnings of 23 million

For at least five years, two men allegedly carried out illegal sales of pharmaceuticals and supplements, amassing millions. They are now facing charges at Söder...

The investor: “The major common diseases are hot again”

She has previously been voted Investor of the Year and will now be moderating The Future of Swedish & Danish Life Science congress. We check the temperature of ...

The New Precise Magazine is Available Now

Download the new issue.

FDA approves Gilead’s HIV injection: “Historic day”

Gilead Sciences’ preventive HIV drug, lenacapavir, was approved on Wednesday by the U.S. Food and Drug Administration (FDA), sparking new hope for finally break...

Large study: The benefits and risks of obesity medications

Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according t...

US Health Secretary Kennedy dismisses all vaccine experts – assembles new committee

Robert F. Kennedy Jr. has dismissed all 17 members of the CDC’s vaccine advisory panel. A new group of experts will be appointed directly by the Health Secretar...

Improved processes and more

Discover the full potential and benefits.

Compact and leak-tight powerhouse

Media-separated solenoid valve VYKA from Festo is virtually leak-free

Unmatched performance and flexibility in its class

The new ZEISS SPECTRUM family is equipped to be the ideal match from measuring small electronics up to larger housings.

The first drugs to slow down Alzheimer’s – but what does it mean for patients?

New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the ri...

Controlled Pneumatics: pushing the boundaries of pneumatics

Pressure, flow rate and movement can now be controlled very precisely, and with exactly the energy actually required. Controlled Pneumatics is the combination o...

Speed meets precision for high-density components

ZEISS METROTOM 800 320 kV.

Björn Arvidsson will lead research and innovation in Region Uppsala

The Swedish life science profile Björn Arvidsson has been appointed Director of Research and Innovation for Region Uppsala.

Automated nitrogen analysis reduces costs per sample

N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo

“What is important is to create an overview and understanding from different perspectives”

Scientist Jochen Schwenk analyses blood proteins using proteomics to improve our understanding of disease and health. This year, he is moderating the Lab & Diag...

Grönt ljus för Gesyntas endometriosstudie i Storbritannien – ”Ett stort steg”

Gesynta Pharma har fått klartecken i Storbritannien för att inleda en fas II-studie med sin läkemedelskandidat inom endometrios.

Virology professor on the threat from X: ”The next pandemic could be worse“

The question is not if, but when we will be affected by a new unknown virus that causes yet another pandemic. Are we sufficiently prepared? "Absolutely not!", r...

The Future of Swedish & Danish Life Science (2026)

Icelandic pharmaceutical company Alvotech to list on Nasdaq Stockholm

One of Iceland's largest companies, the pharmaceutical firm Alvotech, has announced its intention to list on Nasdaq Stockholm.

ZEISS Insights: Measurement of bone plates and screws

Get free access to technical paper.

Achieve Effortless, Standardized Automation with the new ZEISS Automation Interface

Simple interfaces for automated loading of CMMs.

Radioactive tracer to measure effect of drug towards Crohn’s disease

A radioactive tracer developed by Astra Zeneca and the Karolinska Institutet may play a major role for patients with Crohn's disease. That is the belief of Mari...

Positive EMA Decision for BioArctic's New Drug Candidate

Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).